just fetch-gene human UCKL1; the GOA snapshot contained 23 annotations.just deep-research-falcon human UCKL1 --fallback perplexity-lite. Falcon failed with HTTP 402 and the automatic Perplexity-lite fallback failed with HTTP 401/quota exhaustion. No provider-named deep-research file was created. The review therefore relies on the reviewed UniProt record, GOA, cached primary publications, Reactome records, and a targeted PubMed/PMC freshness search.just fetch-gene-pmids human UCKL1 successfully cached every PMID cited by GOA. Additional direct UCKL1 papers found during the freshness search were cached and read.Human UCKL1 is a 548-aa uridine-kinase-family protein with an N-terminal P-loop/uridine-kinase-like region and a C-terminal phosphoribosyltransferase-like region. The decisive biochemical evidence is the 2022 study of purified recombinant UCKL1: it reports that "Both enzymes efficiently phosphorylated uridine and cytidine" and that ATP was the phosphate donor PMID:35583288. The same paper measured UCKL1 kinetic parameters for both substrates and concluded that it is a pyrimidine kinase PMID:35583288. This directly supports uridine kinase activity (GO:0004849), cytidine kinase activity (GO:0043771), UMP salvage, CTP salvage, and the broader pyrimidine-nucleoside salvage process.
A 2024 study provides independent genetic support in Jurkat cells. UCK1/UCK2 double-knockout cells retained uridine-rescue activity; deletion of UCKL1 to make a triple knockout eliminated uridine rescue of de novo pyrimidine-synthesis inhibition PMID:39592843. Because this is a triple-knockout comparison rather than an isolated UCKL1 rescue, it corroborates but does not by itself quantify UCKL1-specific flux.
The C-terminal region was originally modeled as UPRT-like, but the 2002 paper's dual UK/UPRT assignment was a sequence/structure-based proposal, not a direct enzymatic measurement PMID:12199906. The 2022 investigators explicitly stated that UPRT activity was still under examination PMID:35583288. No UPRT molecular-function annotation is therefore warranted from the available evidence.
Reactome places UCKL1 in cytosolic pyrimidine salvage and describes uridine/cytidine phosphorylation, although its event text predates the direct 2022 biochemical demonstration and was initially based on sequence similarity [Reactome:R-HSA-8954327 "Based on sequence similarity, cytosolic uridine-cytidine kinase-like 1 (UCKL1 aka F538) is thought to function as a novel human uridine kinase/uracil phosphoribosyltransferase (Kashuba et al. 2002)."].
The full-length protein was predominantly cytoplasmic when expressed in CV-1 cells, and endogenous UCKL1/F538 staining was almost exclusively cytoplasmic in EBV-negative Burkitt lymphoma cells PMID:12199906. EBV EBNA3 binds UCKL1 and induces nuclear accumulation of the full-length form; the C-terminally truncated isoform 3 remains cytoplasmic PMID:12199906. Thus cytoplasm/cytosol is the best-supported default functional location, whereas nucleus is a real but condition- and isoform-sensitive non-core location.
UniProt lists four splice isoforms. Isoform 3 terminates after residue 395 and lacks most of the C-terminal phosphoribosyltransferase-like region. The 2002 study did not directly measure isoform-specific kinase activity, so the fact that this isoform retains the N-terminal kinase-like domain should be treated as a hypothesis rather than a demonstrated functional distinction.
UCKL1 directly interacts with EBV EBNA3 in yeast two-hybrid and GST pull-down assays PMID:12199906. The generic GO molecular-function term protein binding does not communicate the biological meaning of this host-virus interaction, so the corresponding annotation is retained only as an over-annotated interaction record.
RNF19B/NKLAM is an E3 ubiquitin ligase that binds UCKL1, ubiquitinates it, and lowers its abundance. The abstract-only 2006 paper explicitly reports mammalian-cell interaction and enhanced UCKL1 ubiquitination PMID:16709802 PMID:16709802. The RNF19B-derived generic protein-binding row can therefore be made more informative as ubiquitin protein ligase binding (GO:0031625). Full text is not available in the local cache, but the required interaction and substrate claims are explicit in the abstract.
UCKL1 dosage affects proliferation and apoptosis in tumor-cell models. RNAi in K562 erythroleukemia cells initiated apoptosis, slowed the cell cycle, reduced growth, and increased susceptibility to drug- and NK-mediated killing PMID:19653100. Conversely, overexpression protected tumor cells from NK-mediated and drug-induced apoptosis and increased proliferation PMID:32083188. UCKL1 expression also contributed to the cytotoxic action of the uridine analogue EUrd in temozolomide-resistant glioblastoma-initiating cells PMID:27090194. These are strong disease-model phenotypes, but the available work does not establish whether they are caused by uridine/cytidine kinase activity, another domain, or both; they should not be converted directly into broad normal-process GO annotations.
A 2025 study reports a distinct, context-specific role in TGF-β-activated human cardiac fibroblasts and post-infarction mouse hearts. Endogenous UCK2 and UCKL1 co-immunoprecipitated and colocalized predominantly in the nucleus PMID:41457201. UCKL1 knockdown attenuated fibroblast differentiation, proliferation, and migration; the study proposes that a UCK2/UCKL1 complex recruits TRIM21 to regulate Smurf2/Smad3 signaling PMID:41457201. Kinase-dead proteins retained the profibrotic phenotype PMID:41457201. This recent single-study scaffold model is biologically important but is not treated as a second core evolved function until independently replicated and more precisely mapped.
protein binding with EBNA3 is uninformative and marked over-annotated; generic binding with RNF19B is modified to ubiquitin protein ligase binding.kinase activity, nucleobase-containing small molecule metabolic process, and carbohydrate derivative biosynthetic process) are technically compatible but over-annotated relative to the direct specific terms.CMP biosynthetic process is modified to the more pathway-specific CTP salvage term.